PMID- 35541829
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 8
IP  - 17
DP  - 2018 Feb 28
TI  - Preventive effect of goby fish protein hydrolysates on hyperlipidemia and 
      cardiovascular disease in Wistar rats fed a high-fat/fructose diet.
PG  - 9383-9393
LID - 10.1039/c7ra13102j [doi]
AB  - This study was carried out to investigate the hypolipidemic, cardioprotective and 
      anticoagulant properties of fish goby protein hydrolysates (GPHs) in rats fed a 
      high fat and fructose diet (HFFD). Wistar rats were fed with HFFD for 2 months, 
      coupled with the oral administration of GPHs and undigested goby protein (UGP). 
      Compared with the standard diet, HFFD induced dyslipidemia and liver structure 
      alterations, and increased pancreatic lipase activity. In addition, HFFD caused a 
      significant increase in body weight. Interestingly, administration of UGP and 
      GPHs to HFFD fed rats was efficacious in lowering serum total cholesterol (TC), 
      triglyceride (TG) and low-density lipoprotein cholesterol (LDL-c) as well as 
      hepatic TC and TG, and increased the serum high density lipoprotein cholesterol 
      (HDL-c) content. Moreover, all treatments significantly decreased the atherogenic 
      index and coagulant factor levels (thrombin and prothrombin). UGP and GPH 
      administration also significantly decreased pancreatic lipase activity, which 
      mitigates lipid accumulation. Similarly, UGP and its hydrolysates showed 
      cardioprotective potential revealed by decreasing the risk of atherogenic and 
      coronary artery disease and improving the liver architecture. The ex vivo plasma 
      clotting test showed that GPHs exert a great therapeutic anticoagulant potential. 
      The overall results demonstrated that GPH supplementation can counteract 
      high-fat/fructose diet-induced obesity.
CI  - This journal is (c) The Royal Society of Chemistry.
FAU - Nasri, Rim
AU  - Nasri R
AD  - Laboratory of Enzyme Engineering and Microbiology, University of Sfax, National 
      School of Engineering of Sfax (ENIS) P. O. Box 1173 Sfax 3038 Tunisia 
      abd.ola1502@gmail.com +216 74 275 595 +216 74 274 088.
FAU - Abdelhedi, Ola
AU  - Abdelhedi O
AUID- ORCID: 0000-0001-6829-0014
AD  - Laboratory of Enzyme Engineering and Microbiology, University of Sfax, National 
      School of Engineering of Sfax (ENIS) P. O. Box 1173 Sfax 3038 Tunisia 
      abd.ola1502@gmail.com +216 74 275 595 +216 74 274 088.
FAU - Jemil, Ines
AU  - Jemil I
AD  - Laboratory of Enzyme Engineering and Microbiology, University of Sfax, National 
      School of Engineering of Sfax (ENIS) P. O. Box 1173 Sfax 3038 Tunisia 
      abd.ola1502@gmail.com +216 74 275 595 +216 74 274 088.
FAU - Ben Amor, Ikram
AU  - Ben Amor I
AD  - Centre Regional de Transfusion Sanguine de Sfax, Route El-Ain Km 0.5 CP 3003 Sfax 
      Tunisia.
FAU - Elfeki, Abdelfattah
AU  - Elfeki A
AD  - Laboratory of Animal Ecophysiology, University of Sfax, Faculty of Sciences of 
      Sfax (FSS) P. O. Box 95 Sfax 3052 Tunisia.
FAU - Gargouri, Jalel
AU  - Gargouri J
AD  - Centre Regional de Transfusion Sanguine de Sfax, Route El-Ain Km 0.5 CP 3003 Sfax 
      Tunisia.
FAU - Boualga, Ahmed
AU  - Boualga A
AD  - Laboratoire de Nutrition Clinique et Metabolique, Faculte des Sciences, de la 
      nature et de la vie, Universite d'Oran 1 Ahmed Ben Bella Oran Algeria.
FAU - Karra-Chaabouni, Maha
AU  - Karra-Chaabouni M
AD  - Laboratory of Enzyme Engineering and Microbiology, University of Sfax, National 
      School of Engineering of Sfax (ENIS) P. O. Box 1173 Sfax 3038 Tunisia 
      abd.ola1502@gmail.com +216 74 275 595 +216 74 274 088.
FAU - Nasri, Moncef
AU  - Nasri M
AD  - Laboratory of Enzyme Engineering and Microbiology, University of Sfax, National 
      School of Engineering of Sfax (ENIS) P. O. Box 1173 Sfax 3038 Tunisia 
      abd.ola1502@gmail.com +216 74 275 595 +216 74 274 088.
LA  - eng
PT  - Journal Article
DEP - 20180306
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC9078641
COIS- The authors declare that they have no conflict of interest.
EDAT- 2018/03/06 00:00
MHDA- 2018/03/06 00:01
PMCR- 2018/03/06
CRDT- 2022/05/11 04:04
PHST- 2017/12/07 00:00 [received]
PHST- 2018/02/15 00:00 [accepted]
PHST- 2022/05/11 04:04 [entrez]
PHST- 2018/03/06 00:00 [pubmed]
PHST- 2018/03/06 00:01 [medline]
PHST- 2018/03/06 00:00 [pmc-release]
AID - c7ra13102j [pii]
AID - 10.1039/c7ra13102j [doi]
PST - epublish
SO  - RSC Adv. 2018 Mar 6;8(17):9383-9393. doi: 10.1039/c7ra13102j. eCollection 2018 
      Feb 28.